Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Eris Lifesciences Ltd

ERIS.NS ✓ COMPLIANT ☆ Track — members

NSE India · Healthcare · Pharmaceuticals ·

India Small Cap Analyst: BUY

Last Close

$13.73

▼ -1.21%

Market Cap $1.90B · Vol 59.49K

Key Metrics

P/E Ratio

27.89

FWD: 25.63

Market Cap

$1.90B

Small Cap

Div Yield

0.55%

Semi-annual dividend

EPS Growth

+0.62%

YoY

RSI (14)

30.40

Momentum

Beta

0.73

vs Market

52W High

$19.06

33.88% below

52W Low

$12.58

8.14% above

Volume

59.49K

Avg 99.42K

P/B

4.60

Price-to-book

ROE

18.83%

Return on equity

Free Float

30.08%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Eris Lifesciences Ltd (ERIS.NS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ERIS.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.00%

-6.50%

-3.24%

-5.12%

YTD

-13.02%

-27.11%

+38.79%

+78.47%

Financials & Valuation

TTM · Annual

Total Revenue	$334.85M
Net Income	$69.28M
Revenue Growth (YoY)	+12.97%
Gross Margin	65.65%
Operating Margin	26.86%
Net Profit Margin	20.69%
ROE	18.83%
ROA · ROIC	8.87% · 13.57%

P/E Ratio	27.89
Forward P/E (FY1)	25.63
PEG Ratio	0.38
P/S	5.67
P/B	4.60
P/FCF	354.63
EPS Growth	+0.62%
Outstanding Shares	138.58M

Technical Indicators

50-Day SMA	$14.75
200-Day SMA	$14.97
RSI (14)	30.40
Beta	0.73
52-Week High	$19.06
52-Week Low	$12.58

Volume Today	59.49K
Avg Daily Volume (30D)	99.42K
Relative Volume	0.60x
Volatility (10D)	20.08
Volatility (30D)	23.94
Free Float	30.08%

Analyst Consensus

BUY

Current Price $13.73

Mean Target $17.47

52W Low$12.58 52W High$19.06

Current

Target

$12.58 $19.06

Current Analyst target

+27.27% upside potential · 10 analysts

Identifiers

ExchangeNSE India

FIGIBBG0022GB406

ISININE406M01024

CountryIndia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -1.06% JNJ Johnson & Johnson +0.04% ABBV Abbvie Inc +0.48% NVS Novartis AG +1.24% NOVN.S Novartis AG +1.25%

Company Profile

Eris Lifesciences Limited is an India-based pharmaceutical company. The Company is engaged in the manufacture and marketing of pharmaceutical products. The Company has a presence in major therapies like oral anti-diabetes, insulins, cardiovascular, vitamins/minerals and dermatology. Its flagship therapies include oral anti-diabetes, cardiovascular disease (CVD), and vitamins, minerals and nutrients (VMN). Its emerging therapies consist of dermatology, insulins, women’s health, central nervous system (CNS), oncology, and nephrology. Its portfolio of brands includes Glimisave, Eritel, LNBloc, Olmin, Crevast, Atorsave, Gluxit, Renerve, Zomelis, Cosvate, Tayo, Cyblex, Remylin, Tendia, Rabonik, Ginkocer, Psorid, Raricap, Serlift, and Onabet, among others. Its patient care initiatives (PCI) platform provides various healthcare solutions to its patients. The Company has a manufacturing plant located in Guwahati, Assam.